The effect of febuxostat on diastolic function in hyperuricemic patients with LV diastolic dysfunction

The effect of febuxostat on diastolic function in hyperuricemic patients with LV diastolic dysfunction - The effect of febuxostat on diastolic function

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011961

Enrollment

Registered

2013-11-01

Start date

2012-05-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia with LV diastolic dysfunction

Interventions

febuxisostat benzbromarone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: hyperuricemic patients (>7.0) with LV diastolic dysfunction (E/E' >=15 OR 15>E/E'>=8 & BNP>200)

Exclusion criteria

Exclusion criteria: LV systolic dysfunction (LVEF<50) liver dysfunction (AST or ALT>=100) renal dysfunction (eGFR<30)

Design outcomes

Primary

Measure	Time frame
E', E/E', BNP	—

Secondary

Measure	Time frame
MDA-LDL, TNF-alpha, adiponectin, urinary 8-OHdG, ADMA, xanthine oxidase activity	—

Countries

Japan

Contacts

Public ContactKazuhide Oginio

Tottori University Hospital Division of Clinical Laboratory

ko-36@umin.ac.jp0859-38-6792

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026